Cara Therapeutics Inc (NASDAQ: CARA) suffers from exceptional negative changes in investment behavior: its longer term price trend turned down, its shorter term price trend turned down, the stock fell on very heavy volume, and negative upside/downside volume developed.
The stock is currently unrated.
Current PriceTarget Research Rating
Cara Therapeutics is currently unrated.
Recent Price Action
On 10/16/25, Cara Therapeutics Inc (NASDAQ: CARA) stock declined by -2.4%, closing at $6.48. Moreover, this decline was accompanied by exceptionally high trading volume at 390% of normal. The stock has declined -83.8% during the last week but has been exceptionally strong relative to the market over the last nine months.
Be the first to comment